Cargando…
Bringing cell therapy to tumors: considerations for optimal CAR binder design
Chimeric antigen receptor (CAR)-T cells have revolutionized the immunotherapy of B-cell malignancies and are poised to expand the range of their impact across a broad range of oncology and non-oncology indications. Critical to the success of a given CAR is the choice of binding domain, as this is th...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576856/ https://www.ncbi.nlm.nih.gov/pubmed/37846297 http://dx.doi.org/10.1093/abt/tbad019 |